CCL2 and steatosis: Treating mice with BAR501 improved liver histopathology leading to a 50–70% reduction in the steatosis, fibrosis and inflammatory scores, along with reduction of inflammatory (Il-1β, Il-6, Tnfα, Mcp-1, Rantes and F4/80) and fibrogenic (αSma and Col1α1) genes (Fig. 4E–I; P < 0.05).